Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| CSAPA Apsyades | UNKNOWN |
| OPPELIA-Le triangle | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
A global and integrative treatment of opioid-use disorders (OUD) with opiate maintenance therapy (OMT) and psychosocial interventions is recommended by all current guidelines. Treatment of OUD aim at prevents risks and consequences of opioid use (death by overdose, contamination with infectious diseases, mental and physical degradation, social exclusion and decrease of quality of life). OMT are approved since more than 20 years for OUD and a large number of patients have been treated. Nevertheless, identification of prognosis factors associated with good outcome is still limited. OMT duration, high dosages of OMT and patient good consistency have been identified as good prognosis factors but other individual factors could be involved and explain why OMT isn't as effective for all patients. The investigators assume that social environment, other addictive behaviors, psychiatric comorbidities, personality disorders and pharmacogenetics parameters might be of interest. Association between phenotype/ genotype, safety of OMT and therapeutic outcome will be especially assessed. For voluntary patients specific tools for risk reduction will be implemented (screening of infectious diseases with blood tests and fibrosis with fibroscan). Thus, the aim of TOPAZE study is to highlight prognosis factors for good outcome in the treatment of OUD moderate to severe at 12 months follow-up. Three main axes will be considered: clinical, pharmacological and pharmacogenetics.
All patients with moderate or severe OUD diagnosis (according to Diagnostic and Statistical Manual Diploma in Social Medicine 5) who initiate OMT in addictionology department of Nantes hospital or in addiction care and prevention centers of Nantes could be included. Data will be collected during 3 visits.
During the first visit (inclusion), clinical interview, electrocardiogram, urinary and blood tests (pharmacokinetics and pharmacogenetics analysis) will be provided. Infectious disease screening and fibroscan could be also provided as the patient wishes. Inclusion visit will also correspond to initiation of OMT.
At 6 months follow-up (second visit) clinical interview, electrocardiogram, urinary and blood tests (pharmacokinetics and pharmacogenetics analysis) will be provided.
At 12 months follow-up (final visit) clinical interview, electrocardiogram and urinary test will be provided.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prognosis factor associated with good outcome. | Other | Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up. |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical, pharmacokinetics and pharmacogenetics characteristics associated with good outcome of patients treated with OMT. | Good outcome is defined as early remission of opioid-related disorder according to Diagnostic and Statistical Manual of Mental Disorders Fifth version (none of the diagnostic criteria except craving within last three months) and no initiation or worsening of other addictive behavior (substance use disorders or gambling disorder according to Diagnostic and Statistical Manual of Mental Disorders Fifth version within last 12 months). | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of good outcome after an OMT treatment initiation. | Good outcome is defined as early remission of opioid-related disorder according to Diagnostic and Statistical Manual of Mental Disorders Fifth version (none of the diagnostic criteria except craving within last three months) and no initiation or worsening of other addictive behavior (substance use disorders or gambling according to Diagnostic and Statistical Manual of Mental Disorders Fifth version within last 12 months). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This study will include subjects with an opioid-related disorder for whom an OMT is indicated.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Grall Bronnec | Nantes | 44093 | France | |||
| OPPELIA-Le triangle |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009293 | Opioid-Related Disorders |
| D001519 | Behavior |
| D019966 | Substance-Related Disorders |
| ID | Term |
|---|---|
| D000079524 | Narcotic-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| 12 months |
| Reasons for dropping-out of treatment. | Prevalence of each reason will be described (stopping treatment, death…). | 12 months |
| Clinical characteristics of patients: history of psychoactive substance consumptions, psychiatric comorbidities and addictive behaviors, risky behaviors (intravenous administration, sharing equipment and sexual behavior). | 12 months |
| Number of participants with variation in the cytochrome P450 (CYP) enzyme with focus on CYP2B6, CYP2C19, CYP2D6, CYP3A4 polymorphisms using next-generation sequencing. | Prevalence of CYP2B6, CYP2C19, CYP2D6 and CYP3A4 variants. | At inclusion |
| Pharmacokinetics of OMT elimination. | Residual plasmatic concentration will be considered. | 6 months |
| Number of participants with methadone-associated Q-T interval prolongation as assessed by electrocardiogram [safety]. | Prevalence of methadone-associated Q-T interval prolongation. | 12 months |
| Number of participants who accept to participate to a specific consultation with a hepatologist with a formation in risk reduction. | Prevalence of participants who accept the hepatologist consultation and to be tested with blood tests for viral infections and fibroscan for hepatic fibrosis. | At inclusion |
| Number of participants with variation of the Permeability-glycoProtein (P-gP) using next-generation sequencing. | Prevalence of P-gP variants. | At inclusion |
| Number of participants with variation in the OPRM1 gene (coding for µ receptor) using next-generation sequencing. | Prevalence of OPRM1 variants. | At inclusion |
| Number of participants with urine tests results in accordance with a good compliance [compliance]. | Prevalence of participants with positive urine tests results for OMT without any positive urine tests results for illicit substances or drugs without prescription. | At inclusion |
| Nantes |
| France |